Infinium Pharma — 360° view

Infinium Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹130 crore and net profit of ₹10 crore for the September 2026 quarter.

Infinium Pharma (NSE: INFINIUM-ST) closed at ₹303.00 on 20 Nov 2026. Its market capitalisation is ₹472 crore and it trades at 30.5 times earnings.

Share price
₹303.00 (20 Nov 2026)
Market cap
₹472 Cr (20 Nov 2026)
P/E
30.50 (20 Nov 2026)
Revenue
₹130 Cr (September 2026 quarter)
Net profit
₹10 Cr (September 2026 quarter)
ROCE
12.2% (FY26)
ROE
10.5% (FY26)
Book value
₹83.8 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹319.50 / ₹260.10 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: INFINIUM-ST

Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.